CDK4 and breast carcinoma: With the noticeable exception of resistant MPM_36 cells that displayed a low level of CDK4 phosphorylation (Fig. S1), the presence or absence of CDK4 T172‐phosphorylation thus correctly predicted the sensitivity or insensitivity to CDK4/6 inhibition in MPM cell lines, similarly to our initial observations in breast cancer cell lines [51].